KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Novavax (NVAX) over the last 17 years, with Q3 2025 value amounting to $268.0 million.

  • Novavax's Cash & Equivalents fell 5327.6% to $268.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $268.0 million, marking a year-over-year decrease of 5327.6%. This contributed to the annual value of $530.2 million for FY2024, which is 673.26% down from last year.
  • Latest data reveals that Novavax reported Cash & Equivalents of $268.0 million as of Q3 2025, which was down 5327.6% from $253.7 million recorded in Q2 2025.
  • Novavax's Cash & Equivalents' 5-year high stood at $2.1 billion during Q2 2021, with a 5-year trough of $253.7 million in Q2 2025.
  • Over the past 5 years, Novavax's median Cash & Equivalents value was $651.1 million (recorded in 2023), while the average stood at $973.0 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first soared by 100933.45% in 2021, then crashed by 6322.21% in 2023.
  • Novavax's Cash & Equivalents (Quarter) stood at $1.5 billion in 2021, then decreased by 11.76% to $1.3 billion in 2022, then plummeted by 57.48% to $568.5 million in 2023, then decreased by 6.73% to $530.2 million in 2024, then crashed by 49.45% to $268.0 million in 2025.
  • Its last three reported values are $268.0 million in Q3 2025, $253.7 million for Q2 2025, and $263.3 million during Q1 2025.